Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest

Actuate Therapeutics, Inc. (NASDAQ:ACTU) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 529,786 shares, a growth of 21.1% from the December 15th total of 437,439 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average trading volume of 78,326 shares, the short-interest ratio is currently 6.8 days. Based on an average trading volume of 78,326 shares, the short-interest ratio is currently 6.8 days. Currently, 7.4% of the shares of the stock are short sold.

Insider Transactions at Actuate Therapeutics

In other news, Director Todd S. Thomson sold 280,000 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director owned 904,795 shares of the company’s stock, valued at approximately $5,247,811. The trade was a 23.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 69.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Actuate Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. BIOS Capital Management LP increased its stake in shares of Actuate Therapeutics by 0.9% in the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after acquiring an additional 84,917 shares in the last quarter. Voss Capital LP grew its holdings in Actuate Therapeutics by 213.2% in the third quarter. Voss Capital LP now owns 896,278 shares of the company’s stock worth $5,996,000 after purchasing an additional 610,138 shares during the period. Vanguard Group Inc. increased its stake in Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after purchasing an additional 51,546 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after purchasing an additional 84,561 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Actuate Therapeutics by 98.7% during the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after purchasing an additional 11,105 shares during the period.

Actuate Therapeutics Trading Up 7.0%

Shares of ACTU opened at $5.69 on Monday. The stock has a market capitalization of $132.24 million, a P/E ratio of -6.54 and a beta of -0.15. The firm’s fifty day simple moving average is $6.51 and its two-hundred day simple moving average is $6.97. Actuate Therapeutics has a 12 month low of $5.08 and a 12 month high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Analysts Set New Price Targets

Several analysts have recently weighed in on ACTU shares. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Actuate Therapeutics in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.